Render Target: STATIC
Render Timestamp: 2024-12-02T10:45:45.634Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-09-30 01:58:52.851
Product last modified at: 2024-10-09T13:30:07.703Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

LPCAT1 (E4V4B) Rabbit mAb #57411

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 55
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:2000 - 1:8000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #81677.

    Protocol

    Specificity / Sensitivity

    LPCAT1 (E4V4B) Rabbit mAb recognizes endogenous levels of total LPCAT1 protein. Non-specific staining was observed in pancreas by immunohistochemistry.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala524 of human LPCAT1 protein.

    Background

    LPCAT1 (lysophosphatidylcholine acyltransferase 1), an enzyme that functions in phospholipid metabolism and remodeling, has been reported to be highly expressed and to play a tumor-promoting role in multiple human cancers. Overexpression of LPCAT1 is linked to poor prognosis in breast cancer and hepatocellular carcinoma (HCC) (1,2). In cervical cancer, knockdown of LPCAT1 reduces proliferation, migration, and invasion of cancer cells, and LPCAT1 deletion reduces tumor growth and metastasis in mice through Jak2/Stat3 signaling (3). In endometrial cancer, LPCAT1 enhances stemness and metastasis through TGF-β signaling (4). In non-small cell lung cancer (NSCLC), LPCAT1 upregulates EGFR/PI3K/Akt signaling, promoting resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) (5). Due to its high expression in cancer, as well as its role in tumor promotion and drug resistance, LPCAT1 is a potential therapeutic target and prognostic biomarker.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.